Skip to main content
Caplight Logo









CureMatch

CureMatch

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.curematch.com/

Last Round

VC Round

Jun 1, 2021

Total Funding Raised

$45,000

Company Overview

CureMatch is a digital health company that provides a decision support system to guide oncologists in the selection of personalized cancer drug combinations based on a patient's molecular tumor profile.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Medical AI, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Usage-Based SaaS, Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

precision oncologycombination therapyoncology decision supportoncology AIcancer therapy matchingprecision medicinemolecular profiling analysisNGS data interpretationclinical trial intelligencepatient stratificationclinical decision supportCPT code reimbursementnext-generation sequencingNGS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CureMatch Comparables

Compare CureMatch with similar companies based on industry and business-model similarity.

CureMatch comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GenomOncology
82%
Clarified Precision Medicine
81%
OncoDNA
81%

CureMatch Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 1, 2021
GrantJun 14, 2018
GrantAug 18, 2017
SeedAug 15, 2017

Key People

Founding team and executive leadership

Navid Alipour

Co-Founder CEO Board Member

Founding Team

CureMatch Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2021

    Raised a VC Round with Unitleader as an investor.

  • Jun 14, 2018

    $35K grant received from JPMorgan Chase and World Trade Center San Diego.

CureMatch Filings

Explore SEC and related filing metadata, where available.

CureMatch filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CureMatch's valuation, stock price, and market status.

Is CureMatch a public or private company?

CureMatch is a private company.

What is the current stock price of CureMatch?

CureMatch is a private company with no public stock price. No recent secondary market data is available.

How much is CureMatch worth (valuation)?

Valuation information for CureMatch is not publicly available.

Can I buy CureMatch stock?

CureMatch shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CureMatch's last funding round?

CureMatch's most recent funding round was VC Round on June 1, 2021.

Who are the main investors in CureMatch?

Key investors in CureMatch include Analytics Ventures, World Trade Center San Diego MetroConnect, Unitleader, JPMorgan Chase & Co..

Will CureMatch IPO soon?

No public IPO plans have been announced for CureMatch.

How can I track CureMatch secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CureMatch's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range21
Year Founded2015
Last FundingJun 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?